Unlikely to cause harm — often a labeling or packaging issue.
Subpotent Drug: One lot of product does not meet the product specification for Assay test at 3 month long term stability condition.
| Brand name | AMLODIPINE BESYLATE |
| Generic name | AMLODIPINE BESYLATE |
| Active ingredient(s) | AMLODIPINE BESYLATE |
| Distributed by / for | Cipla USA, Inc. 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise FL 33323 UPC 369097128159 |
| NDC | 69097-128-15 |
| Full product label | Amlodipine Besylate USP 10 mg Tablets, 1000-count bottles, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc. 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise FL 33323 UPC 369097128159, NDC 69097-128-15 |
| Recalling firm | InvaGen Pharmaceuticals, Inc. |
| Distribution | Nationwide with the United States |
| Quantity | 2880 bottles |
| Recall initiated | 2018-10-03 |
| Report date | 2018-10-17 |
| Recall completed | 2021-07-13 |
| Recall number | D-0012-2019 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | Hauppauge NY United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗